J. Goldman & CO LP Paratek Pharmaceuticals, Inc. Transaction History

J. Goldman & CO LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.52 - $2.8 $238,746 - $439,796	-157,070 Reduced 17.16%	758,431 $1.68 Million
Q1 2023 May 15, 2023	BUY	$1.37 - $2.54 $1.19 Million - $2.2 Million	865,126 Added 1717.37%	915,501 $2.33 Million
Q4 2022 Feb 14, 2023	SELL	$1.67 - $2.51 $682,403 - $1.03 Million	-408,625 Reduced 89.03%	50,375 $94,000
Q3 2022 Nov 14, 2022	BUY	$1.96 - $2.93 $859,748 - $1.29 Million	438,647 Added 2155.2%	459,000 $1.18 Million
Q2 2022 Aug 15, 2022	SELL	$1.73 - $3.09 $1.79 Million - $3.2 Million	-1,036,278 Reduced 98.07%	20,353 $39,000
Q1 2022 May 16, 2022	BUY	$2.94 - $4.77 $3.11 Million - $5.04 Million	1,056,631 New	1,056,631 $3.14 Million
Q3 2020 Nov 16, 2020	SELL	$4.19 - $6.69 $349,169 - $557,504	-83,334 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$2.97 - $5.22 $310,130 - $545,077	-104,421 Reduced 55.62%	83,334 $435,000
Q1 2020 May 15, 2020	BUY	$2.67 - $4.97 $234,305 - $436,142	87,755 Added 87.76%	187,755 $591,000
Q4 2019 Feb 14, 2020	SELL	$2.93 - $4.5 $171,844 - $263,925	-58,650 Reduced 36.97%	100,000 $403,000
Q3 2019 Nov 14, 2019	BUY	$3.08 - $5.76 $488,642 - $913,824	158,650 New	158,650 $685,000

1.54M

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.